Rxsight, INC

RxSight, Inc. announced its second quarter 2026 financial results, reporting total revenue of $33.7 million, including $6.5 million from the Alcon collaboration, while product sales declined 19% year-over-year.

RxSight, Inc. announces a leadership transition with Aziz Mottiwala appointed as President and CEO, succeeding Dr. Ron Kurtz, who will move to Chief Medical Officer.

RxSight, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the re-election of three Class II directors and the ratification of its independent auditor.

RxSight, Inc. announced its first quarter 2026 financial results, reporting $30.9 million in sales and maintaining its full-year revenue and gross margin guidance.

RxSight, Inc. filed an amended 8-K to disclose the exact sign-on bonus amount and correct the stock option vesting schedule for its Chief Financial Officer, Mark Wilterding.

RxSight, Inc. announced its fourth quarter and full year 2025 financial results, showing strong Light Adjustable Lens growth but overall revenue decline and increased net losses, alongside a conservative 2026 guidance.

RxSight, Inc. reports a 14.1% revenue decrease in Q3 2025 driven by a significant drop in LDD sales, despite continued growth in Light-Adjustable Lens (LAL) implants, leading to increased operating losses and ongoing litigation.

RxSight, Inc. reported a significant increase in net loss for Q2 2025, driven by a sharp decline in Light Delivery Device (LDD) sales and rising operating expenses, despite growth in Light-Adjustable Lens (LAL) implants and improved gross margin.

RxSight's Q1 2025 revenue increased by 28.4% year-over-year, driven by strong adoption of its Light Adjustable Lens (LAL) system.

RxSight, Inc., a commercial-stage medical technology company, announced a 59% increase in revenue for Q3 2024, driven by significant adoption of its innovative Light Adjustable Lens system.

RxSight, Inc. reports a significant increase in revenue for the second quarter of 2024, fueled by strong adoption of its Light Adjustable Lens system and a growing installed base of Light Delivery Devices.

RxSight, Inc. announced a significant increase in revenue for the first quarter of 2024, primarily driven by a substantial rise in Light Adjustable Lens (LAL) sales.

RxSight, Inc. reported a 3.9% decrease in total sales for 2025 to $134.5 million, driven by slower adoption of its Light Delivery Devices, despite an increase in Light Adjustable Lens sales and improved gross margin.

RxSight, Inc. announces significant revenue increase and expansion in its LDD installed base, solidifying its position in the premium IOL market.

RxSight, Inc. reports a significant increase in revenue and installed base for its Light Adjustable Lens system in its 2023 annual filing.

Aziz Mottiwala, President and CEO and a Director of RxSight, Inc., reported multiple transactions in common stock on July 24, 2026.

Robert Keith Warner, a Director at RxSight, Inc., acquired 37,037 shares of common stock on June 17, 2026, as per a Form 4 filing.

RxSight, Inc. reports that Director Robert J. Palmisano acquired 37,037 shares of common stock on June 17, 2026, as part of his compensation.

RxSight, Inc. Director Shweta Maniar acquired 37,037 shares of common stock through restricted stock units.

Director Tamara Fountain acquired 37,037 shares of common stock in RxSight, Inc. on June 17, 2026, as detailed in a Form 4 filing.

William J. Link, PhD, a Director at RxSight, Inc., has acquired 37,037 shares of common stock, increasing his beneficial ownership.

RxSight, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 16, 2026, with April 21, 2026, as the record date.

RxSight, Inc. will hold its annual meeting of stockholders on June 3, 2025, to elect directors, approve executive compensation, and ratify the appointment of Ernst & Young LLP as the independent auditor.

RxSight, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 3, 2025, to vote on director elections, executive compensation, and auditor ratification.

RxSight, Inc. will hold its annual stockholders meeting on June 6, 2024, to vote on the election of directors, executive compensation, and the ratification of the company's independent auditor.

RxSight, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 6, 2024, to vote on director elections, executive compensation, and auditor ratification.

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has reported beneficial ownership of 7.3% of RxSight, Inc. common stock.

The Vanguard Group filed an amended Schedule 13G for RxSight Inc, reporting 0% beneficial ownership due to an internal reporting realignment.

Artisan Partners Asset Management Inc. and its affiliates have reported a 5.2% passive beneficial ownership stake in RxSIGHT, Inc. common stock.

RA Capital Management and its affiliates have reported a 0.0% beneficial ownership in RxSight, Inc., indicating a full divestment of their previous holdings.

Artisan Partners Asset Management Inc. and its affiliates have filed an amended Schedule 13G, disclosing a reduced beneficial ownership of 4.3% in RxSIGHT, INC. common stock.

Millennium Management LLC and its affiliates have reported a 5.4% beneficial ownership stake in RxSight, Inc., holding 2,193,062 shares of common stock.